Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (456)	4/23/2003 9:58:57 PM
From: SemiBull	Read Replies (1) \| Respond to of 668

Curis jumps on patent for anti-cancer compounds Wednesday April 23, 3:44 pm ET NEW YORK, April 23 (Reuters) - Shares of tiny drugmaker Curis Inc (NasdaqNM:CRIS - News) jumped on Wednesday after the company said it had a won a U.S. patent on a group of compounds that have potential to kill tumor cells. Shares of the Cambridge, Massachusetts-based company were up $1.24, or 85 percent, to $2.69 in late-afternoon trade on the Nasdaq. Curis said it had won a patent on synthetically made compounds that selectively inhibit a chemical pathway in the body that is controlled by a protein called Hedgehog. Curis said it is already developing one such compound, named CUR-61414, as a possible drug for basal cell carcinoma, a common type of skin cancer caused by exposure to the sun. It said research suggests its experimental drug can selectively kill tumor cells while not harming adjacent healthy cells.